EARLY relapse within three months following definitive therapy dramatically reduces long-term survival in oral tongue cancer. In a retrospective cohort analysis of 944 patients with oral tongue squamous cell carcinoma receiving curative surgical resection, rapid relapse emerged as one of the strongest adverse prognostic indicators. Patients experiencing recurrence within three months demonstrated an alarming 5-year overall survival rate of 46.1%, contrasted sharply with 88.5% observed among individuals without early disease relapse.
Multivariable logistic regression revealed distinct clinicopathological and metabolic drivers governing treatment failure. Primary tumor stage T2 to T4 expanded the likelihood of early relapse by up to nearly sixfold. Extensive regional nodal involvement at stage N3 presented an odds ratio of 5.39, while microscopically positive resection margins yielded an odds ratio of 5.22. Pathological perineural invasion doubled early failure odds.
Preoperative metabolic activity measured via primary tumor PET SUVmax further served as a key predictive continuous marker, generating a 14% risk increase for every single unit increment in tracer uptake.
To translate complex biological dynamics into bedside utility, investigators built a dedicated predictive nomogram integrating tumor extent, nodal status, resection margin status, perineural invasion, metabolic PET values, and initial management protocols. Internal validation utilizing cross-validation algorithms yielded area under the curve values of 0.715 and 0.736 alongside strong calibration accuracy.
The stratification separates low-risk individuals needing standard monitoring from intermediate and high-risk tiers requiring escalated surveillance pathways.
Adjuvant concurrent chemoradiotherapy demonstrated a notable protective benefit, yielding a 66% drop in early failure alongside substantial survival enhancement. Given that traditional guidelines mandate initial restaging imaging only several months after concluding adjuvant protocols, highly vulnerable cohorts remain undetected during vulnerable windows.
Investigators advise baseline PET-CT restaging within four to six weeks post-surgery for predicted failure probabilities exceeding 50%. Immediate metabolic checks illuminate microscopic residual disease before extensive growth occurs, facilitating timely radiation field adaptation, prompt systemic therapy, or salvage intervention.
Reference
Kim Y et al. Clinical Impact of Rapid Recurrence in Oral Tongue Squamous Cell Carcinoma and a Nomogram for Early Identification of High-Risk Patients. Clin Exp Otorhinolaryngol. 2026;19(3):293-304.
ZAY WIN HTAI on adobe stock
Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.
